Skip to main content
SpringerLink
Log in

Acamprosate: clinical data

  • Chapter
Drugs for Relapse Prevention of Alcoholism

Part of the book series: Milestones in Drug Therapy MDT ((MDT))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Boismare F, Daoust M, Moore N, Saligaut C, Lhuintre JP, Chrétien P, Durlach J (1984) an homotaurinate derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved? Pharmacol Biochem Behav 21: 787–789

    Article  PubMed  CAS  Google Scholar 

  2. Le Magnen J, Tran G, Durlach J, Martin C (1987) Dose-dependent suppression of the high alcohol intake of chronically intoxicated rats by Ca-acetyl homotaurinate. Alcohol Alcoholism 4: 97–102

    Google Scholar 

  3. Lhuintre JP, Daoust M, Moore ND, Chretien P, Saligaut C, Tran G, Boismare F, Hillemand B (1985) Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. Lancet 1: 1014–1016

    PubMed  CAS  Google Scholar 

  4. Hillemand B, Lhuintre JP, Steru L, Boismare F, Daoust M, Moore N et al. (1989) Multicenter trial of calcium bis (acetylhomotaurinate) in treatment of alcohol dependence. Rev de L’Alcohol 34: 9–28

    Google Scholar 

  5. Mann K (2004) Pharmacotherapy of alcohol dependence: a review of the clinical data. CNS Drugs 8: 485–504

    Google Scholar 

  6. Mann K, Lehert P, Morgan MY (2004) The efficacy of acamprosate in maintaining abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res 28: 51–63

    PubMed  Google Scholar 

  7. Al Quatari M, Bouchenafa O, Littleton J (1998) Mechanisms of action of acamprosate. Part II Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex. Alcohol Clin Exp Res 22: 810–814

    Google Scholar 

  8. Littleton J, Zieglgansberger W (2003) Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. Am J Addict 12(Suppl 1): S3–S11

    PubMed  Google Scholar 

  9. Littleton J (1995) Acamprosate in alcohol dependence: how does it work? Addiction 90: 1179–1188

    Article  PubMed  CAS  Google Scholar 

  10. Rammes G, Mahal B, Putzke J, Parsons C, Spielmanns P, Pestel E, Spanagel R, Zieglgänsberger W, Schadrack J (2001) The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology 40: 749–760

    Article  PubMed  CAS  Google Scholar 

  11. Naassila M, Hammoumi S, Legrand E, Durbin P, Daoust M (1998) Mechanisms of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain. Alcohol Clin Exp Res 22: 802–809

    PubMed  CAS  Google Scholar 

  12. Popp RL, Lovinger DM (2000) Interaction of acamprosate with ethanol and spermine on NMDA receptors in primary cultured neurons. Eur J Neurosci 394: 221–231

    CAS  Google Scholar 

  13. Harris BR, Prendergast MA, Gibson DA, Rogers DT, Blanchard JA, Holley RC, Fu MC, Hart SR, Pedigo NW, Littleton JM (2002) Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcohol Clin Exp Res 26: 1779–1793

    PubMed  CAS  Google Scholar 

  14. Bäckstræm S, Bachteler D, Koch S, Hyytiä P, Spanagel R (2003) The mGluR5antagonist MPEP prevents alcohol seeking and relapse behavior. Eur J Neurosci 29: 921–928

    Google Scholar 

  15. Chiamulera C, Epping-Jordan MP, Zocchi A, Marcon C, Cottiny C, Tacconi S, Corsi M, Orzi, F, Conquet F (2001) Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nature Neurosci 4: 873–874

    Article  PubMed  CAS  Google Scholar 

  16. Sass H, Soyka M, Mann K, Zieglgansberger W (1996) Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 53: 673–680

    PubMed  CAS  Google Scholar 

  17. Whitworth AB, Fischer F, Lesch OM, Nimmerrichter A, Oberbauer H, Platz T, Potgieter A, Walter H, Fleischhacker WW (1996) Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 347: 1438–1442

    PubMed  CAS  Google Scholar 

  18. Rousseaux JP, Hers D, Ferauge M (1996) Does acamprosate influence alcohol consumption of weaned alcoholics? J Pharm Belg 51: 65–68

    Google Scholar 

  19. Namkoong K, Lee B-O, Lee P-G, Choi M-J, Lee E, and Korean Acamprosate Clinical Trial Investigators (2003) Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study. Alcohol Alcoholism 38: 135–141

    Article  CAS  Google Scholar 

  20. Chick J, Howlett H, Morgan MY, Ritson B for the UKMAS investigators (2000) United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcoholism 35: 176–187

    CAS  Google Scholar 

  21. Pelc I, Verbanck P, Le Bon O, Gavrilovic M, Lion K, Lehert P (1997) Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. Br J Psychiat 170: 73–77

    Google Scholar 

  22. Paille FM, Guelfi JD, Perkins AC, Royer RJ, Steru L, Parot P (1995) Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcoholism 30: 239–247

    CAS  Google Scholar 

  23. Garbutt JC, West S, Carey TS, Lohr KN, Crews FT (1999) Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 281: 1318–1325

    Article  PubMed  CAS  Google Scholar 

  24. Kranzler HR, Van Kirk J (2001) Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 25: 1335–1341

    PubMed  CAS  Google Scholar 

  25. Hopkins JS, Garbutt JC, Poole CL, West SL, Carey TS (2002) Naltrexone and acamprosate: meta-analysis of two medical treatments for alcoholism. Alcohol Clin Exp Res 26(Suppl): 130A, 751

    Google Scholar 

  26. Schoechlin C, Engel RR (2000) Meta-analysis of pharmotherapeutic trials. In: G Zernig, A Saria, M Kurz, S O’Malley (eds): Handbook of Alcoholism. Innsbruck University Press, 339–351

    Google Scholar 

  27. Slattery J, Chick J, Cochrane M, Craig J, Godfrey C, Macpherson K, Parrott S, Quinn S, Tochel C, Watson H (2003) Prevention of relapse in alcohol dependence. Health Technology Assessment Report 3, Glasgow: Health Technology Board of Scotland

    Google Scholar 

  28. Berglund M, Thelander S, Salaspuro M, Franck J, Andreasson S, Ojehagen A (2003) Treatment of alcohol abuse: an evidence-based review. Alcohol Clin Ex Res 27: 1645–1656

    Google Scholar 

  29. Annemans L, Vanoverbeke N, Tecco J, D’Hooghe D (2000) Economic evaluation of campral (acamprosate) compared to placebo in maintaining abstinence in alcohol-dependent patients. Eur Addict Res 6: 71–78

    Article  PubMed  CAS  Google Scholar 

  30. Bühringer G, Augustin R, Bergmann E. Bloomfield K, Funk W, Junge B, Kraus L, Merfert-Diete C, Rumpf HJ, Simon R et al (2000) Alkoholkonsum und alkoholbezogene Störungen in Deutschland, Schriftenreihe des Bundesministeriums für Gesundheit Band 128, Nomos, Baden-Baden

    Google Scholar 

  31. Rubio G, Jimenez-Arriero MA, Ponce G, Palomo T (2001) Naltrexone versus acamprosate: one year follow-up of alcohol dependence of alcohol dependence treatment. Alcohol Alcoholism 36: 419–425

    Article  CAS  Google Scholar 

  32. Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, Kämpf P, Stracke R, Baehr M, Naber D et al. (2003) Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 60: 92–99

    Article  PubMed  CAS  Google Scholar 

  33. The COMBINE Study Research Group (2003) Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: (The COMBINE Study): a pilot feasibility study. Alcohol Clin Exp Res 7: 1107–1122

    Google Scholar 

  34. Gerra G, Caccavari R, Delsignore R, Bocchi R, Fertonani G, Passeri M (1992) Effects of fluoxetine and Ca-acetyl-homotaurinate on alcohol intake in familial and non-familial alcoholic patients. Curr Therap Res Clin Exp 52: 291–295

    Google Scholar 

  35. Besson J, Aeby F, Kasas A, Lehert P, Potgieter A (1998) Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res 22: 573–579

    PubMed  CAS  Google Scholar 

  36. Pelc I, Ansoms C, Lehert P, Fischer F, Fuchs WJ, Landron F, Pires Preto AJ, Morgang MY (2002) The European NEAT program: an integrated approach using acamprosate and psychosocial support for the prevention of relapse in alcohol-dependent patients with a statistical modelling of therapy success prediction. Alcohol Clin Exp Res 26: 1529–1538

    PubMed  Google Scholar 

  37. De Wildt WAJM, Schippers GM, Van den Brink W, Potgieter AS, Deckers F, Bets D (2002) Does psychosocial treatment enhance the efficacy of acamprosate in patients with alcohol problems? Alcohol Alcoholism 4: 375–382

    Google Scholar 

  38. Feeney GF, Young RM, Connor JP, Tucker J, McPherson A (2002) Cognitive behavioural therapy combined with the relapse-prevention medication acamprosate: are short-term outcomes for alcohol dependence improved? Aust NZ J Psychiatry 36: 622–628

    Article  Google Scholar 

  39. Mann K, Smolka M, Spanagel R, Heinz A. Searching for the acamprosate and naltrexone responders: PROJECT PREDICT. Alcoholism Clin Exp Res; in press

    Google Scholar 

  40. Bachteler D, Economidou D, Danysz W, Ciccocioppo R, Spanagel R (2004) The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat. Neuropsychopharmacology; in press

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Addictive Behavior and Addiction Medicine, University of Heidelberg, Central Institute of Mental Health, J 5, 68159, Mannheim, Germany

    Karl F. Mann

Authors
  1. Karl F. Mann
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Abteilung für Psychopharmakologie, Universit ät Heidelberg, J5, Zentralinstitut für Seelische Gesundheit, 68159, Mannheim, Germany

    Rainer Spanagel

  2. Klinik für Abhängiges Verhalten und Suchtmedizin, J5, Zentralinstitut für Seelische Gesundheit, 68159, Mannheim, Germany

    Karl F. Mann

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Birkhäuser Verlag/Switzerland

About this chapter

Cite this chapter

Mann, K.F. (2005). Acamprosate: clinical data. In: Spanagel, R., Mann, K.F. (eds) Drugs for Relapse Prevention of Alcoholism. Milestones in Drug Therapy MDT. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7305-9_8

Download citation

Publish with us

Policies and ethics

Search

Navigation